10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2021 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 18, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 7,071 | 4,495 | 3,687 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 1,491 | 1,195 | 1,078 |
| Amortization of intangible assets | 2,047 | 2,132 | 1,936 |
| Share-based compensation | 640 | 546 | 519 |
| Investing and financing losses, net | 55 | 425 | 184 |
| Loss on extinguishment of debt | 63 | ||
| Trade receivables | (383) | (924) | (275) |
| Inventories | (456) | (493) | (593) |
| Prepaid expenses and other assets | (312) | (627) | (138) |
| Trade accounts payable and other liabilities | 1,288 | 1,766 | 220 |
| Income taxes | (908) | (614) | (545) |
| Net Cash From Operating Activities | 10,533 | 7,901 | 6,136 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,885) | (2,177) | (1,638) |
| Acquisitions of businesses and technologies, net of cash acquired | (187) | (42) | (170) |
| Proceeds from business dispositions | 134 | 58 | 48 |
| Purchases of investment securities | (173) | (83) | (103) |
| Proceeds from sales of investment securities | 77 | 10 | 21 |
| Other | 26 | 19 | 27 |
| Net Cash From (Used in) Investing Activities | (2,008) | (2,215) | (1,815) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | (204) | 2 | |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 4 | 1,281 | 1,842 |
| Repayments of long-term debt and debt with maturities over 3 months | (48) | (1,333) | (3,441) |
| Purchases of common shares | (2,299) | (403) | (718) |
| Proceeds from stock options exercised | 255 | 245 | 298 |
| Dividends paid | (3,202) | (2,560) | (2,270) |
| Other | (11) | ||
| Net Cash From (Used in) Financing Activities | (5,494) | (2,779) | (4,289) |
| Effect of exchange rate changes on cash and cash equivalents | (70) | 71 | (16) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 2,961 | 2,978 | 16 |
| Cash and Cash Equivalents, Beginning of Year | 6,838 | 3,860 | |
| Cash and Cash Equivalents, End of Year | 9,799 | 6,838 | 3,860 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,941 | 970 | 930 |
| Interest paid | 544 | 549 | 677 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |